文献速递心脑血管急症重症综合管理与镇静镇痛

成人苯二氮䓬难治性癫痫持续状态中左乙拉西坦负荷剂量的评估

Evaluation of levetiracetam loading dose in adult patients with benzodiazepine-refractory status epilepticus.
PubMed 文献 · Am J Emerg Med · 2024-09-02
一句话结论在成人苯二氮䓬难治性癫痫持续状态中,左乙拉西坦负荷剂量≤20、21–39、≥40 mg/kg 三组的60分钟止惊率无显著差异,但≥40 mg/kg组插管率更高(45.8% vs 28.2% vs 26.8%,p=0.040)。

本研究为单中心回顾性队列研究,纳入2016年4月1日至2023年8月31日成人苯二氮䓬难治性癫痫持续状态患者218例,按左乙拉西坦负荷剂量分为≤20 mg/kg(LEVlow,平均14.5 mg/kg)、21–39 mg/kg(LEVmed,平均28.8 mg/kg)、≥40 mg/kg(LEVhigh,平均48.8 mg/kg)三组。主要终点60分钟止惊率三组无显著差异(92.9% vs 89.3% vs 84.7%,p=0.377);60分钟至24小时癫痫复发率亦无差异(32.1% vs 32.0% vs 28.8%,p=0.899)。LEVhigh组插管率(45.8%)高于LEVmed组(28.2%)和LEVlow组(26.8%)(p=0.040)。作者认为左乙拉西坦负荷剂量未显著影响60分钟止惊率或24小时复发率,但>40 mg/kg与更高插管率相关,需进一步研究确定最佳负荷剂量。

要点

  • 成人苯二氮䓬难治性癫痫持续状态中,左乙拉西坦负荷≤20、21–39、≥40 mg/kg三组60分钟止惊率无显著差异(92.9% vs 89.3% vs 84.7%,p=0.377)。
  • 左乙拉西坦负荷后60分钟至24小时癫痫复发率三组无显著差异(32.1% vs 32.0% vs 28.8%,p=0.899)。
  • 左乙拉西坦负荷>40 mg/kg组插管率45.8%,高于21–39 mg/kg组28.2%和≤20 mg/kg组26.8%(p=0.040)。
  • 作者认为需进一步研究确定苯二氮䓬难治性癫痫持续状态中左乙拉西坦的最佳负荷剂量。

适用人群与场景

  • 成人苯二氮䓬难治性癫痫持续状态患者,接受左乙拉西坦治疗,纳入时间为2016年4月1日至2023年8月31日。
  • 排除对左乙拉西坦有记录的超敏反应者、妊娠或囚犯患者、在左乙拉西坦之前接受其他抗癫痫药物者。
  • 排除其他可识别病因的癫痫持续状态,包括高血糖、低血糖、低钠血症或心脏骤停后患者。

诊断标准与关键阈值

  • 癫痫持续状态定义为持续癫痫活动大于5分钟或反复癫痫发作且未恢复至基线。
  • 苯二氮䓬难治性癫痫持续状态定义为尽管接受苯二氮䓬治疗仍持续癫痫活动。

处置流程与药物剂量

  • 苯二氮䓬难治性癫痫持续状态的治疗包括左乙拉西坦负荷剂量范围20 mg/kg至60 mg/kg,最大剂量4500 mg。
  • 研究按左乙拉西坦负荷剂量分为≤20 mg/kg(LEVlow,平均14.5 mg/kg)、21–39 mg/kg(LEVmed,平均28.8 mg/kg)、≥40 mg/kg(LEVhigh,平均48.8 mg/kg)三组。

研究设计与关键结果

  • 研究类型为单中心、回顾性队列研究;筛查740例,纳入218例成人苯二氮䓬难治性癫痫持续状态患者。
  • 主要终点60分钟止惊率(左乙拉西坦给药后60分钟内无需额外抗癫痫药物):LEVlow组92.9% vs LEVmed组89.3% vs LEVhigh组84.7%,p=0.377。
  • 次要终点60分钟至24小时癫痫复发率(以脑电图阳性或需额外抗癫痫药物定义):LEVlow组32.1% vs LEVmed组32.0% vs LEVhigh组28.8%,p=0.899。
  • 次要终点插管率:LEVhigh组45.8% vs LEVmed组28.2% vs LEVlow组26.8%,p=0.040。
  • 亚组分析评估了充足苯二氮䓬负荷剂量和门诊左乙拉西坦使用的影响。

证据类型、等级与局限

  • 证据类型:单中心、回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为左乙拉西坦负荷剂量未显著影响60分钟止惊率或24小时复发率,但>40 mg/kg与更高插管率相关,需进一步研究确定最佳负荷剂量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Status epilepticus (SE) is a neurologic emergency defined as continued seizure activity greater than five minutes or recurrent seizure activity without return to baseline. Benzodiazepine-refractory SE is continuous seizure activity despite treatment with a benzodiazepine. Treatment of benzodiazepine-refractory SE includes levetiracetam with loading doses ranging from 20 mg/kg to 60 mg/kg up to a maximum dose of 4500 mg. While levetiracetam has minimal adverse effects, there is currently a lack of studies directly comparing the safety and efficacy of various loading doses of levetiracetam.

OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of three loading doses of levetiracetam in the setting of benzodiazepine-refractory SE.

METHODS: This was a single center, retrospective cohort study of adult patients with benzodiazepine-refractory SE who were treated with levetiracetam from April 1, 2016, to August 31, 2023. Patients with documented hypersensitivity to levetiracetam, those who were pregnant or incarcerated and patients who received an alternative antiepileptic drug (AED) prior to levetiracetam were excluded. Patients with other identifiable causes of SE including hyperglycemia, hypoglycemia, hyponatremia or who were post cardiac arrest were also excluded. Patients were divided into three arms based on loading dose of levetiracetam administered (≤20 mg/kg [LEVlow], 21--39 mg/kg [LEVmed] or ≥40 mg/kg [LEVhigh]). The primary endpoint was the rate of seizure termination, defined as the lack of need for an additional AED within 60 min following levetiracetam administration. Secondary outcomes included the rate of intubation, and recurrent seizure activity 60 min to 24 h post seizure termination as defined by positive EEG results or need for an additional AED. Subgroup analyses were performed to assess the influence of adequate loading doses of benzodiazepines, and outpatient levetiracetam use.

RESULTS: Overall, 740 patients were screened for inclusion, with 218 patients being included in the primary analysis. Patients were divided into three groups with an average levetiracetam loading dose of 14.5 mg/kg in the LEVlow group, 28.8 mg/kg in the LEVmed group, and 48.8 mg/kg in the LEVhigh group. There was no difference in rates of seizure termination at 60 min (92.9% LEVlow vs 89.3% LEVmed vs 84.7% LEVhigh; p = 0.377). Additionally, no difference was found in rates of recurrent seizure activity between 60 min and 24 h post levetiracetam loading dose (32.1% LEVlow vs 32.0% LEVmed vs 28.8% LEVhigh; p = 0.899). However, the LEVhigh group did have a higher rate of intubation (45.8%) compared to the LEVmed (28.2%) and LEVlow (26.8%) group (p = 0.040).

CONCLUSION: The loading of levetiracetam did not result in a statistically significant difference in rate of seizure termination at 60 min nor did it appear to impact the rate of recurrent seizures at 24 h. However, we did find higher rates of intubation in patients who received levetiracetam >40 mg/kg. Further research is warranted to determine the optimal loading dose of levetiracetam in benzodiazepine-refractory SE.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Schowe C, Frick CD, Weitkamp LU, et al. Evaluation of levetiracetam loading dose in adult patients with benzodiazepine-refractory status epilepticus. Am J Emerg Med. 2024. PMID: 39270551. doi:10.1016/j.ajem.2024.09.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。